UCB/Celltech Merger Nears Completion: Integration To Commence Under CEO Doliveux
This article was originally published in The Pink Sheet Daily
Executive Summary
Celltech's TNF inhibitor CDP-870 is crown jewel of $2.7 bil. acquisition; a BLA filing is expected in 2007. UCB CEO Roch Doliveux will continue to serve as chief executive, while Celltech CEO Goran Ando will become deputy CEO.
You may also be interested in...
UCB/Celltech Exec Chairman Will Be UCB Pharma’s Doliveux
Current UCB Group Executive Committee Chairman Georges Jacobs will be replaced by UCB Pharma CEO Roch Doliveux effective Jan. 1. Jacobs will chair the board of directors.
UCB/Celltech Exec Chairman Will Be UCB Pharma’s Doliveux
Current UCB Group Executive Committee Chairman Georges Jacobs will be replaced by UCB Pharma CEO Roch Doliveux effective Jan. 1. Jacobs will chair the board of directors.
Celltech Finds CDP-870 Partner In UCB; BLA Filing Expected By 2007
The licensing agreement gives Celltech a means through which to commercialize the TNF inhibitor should the companies' proposed $2.7 bil. merger agreement fall through. UCB/Celltech will be fifth largest biotech company worldwide.